首頁 > 市場調查報告書 > 製藥

藥物開發

市場調查報告書

商品編碼

1733269

藥物發現資訊學市場按應用、功能、最終用戶和地區分類（2026 年至 2032 年）

Drug Discovery Informatics Market By Application (Drug Discovery, Drug Development), By Function (Sequence Analysis Platforms, Docking), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations), And Region For 2026-2032

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

藥物發現資訊學市場評估（2026-2032）

由於藥物發現日益複雜、藥物開發時間縮短以及對個人化治療的重視等因素，對藥物發現資訊學的需求正在擴大。基因組學、蛋白質組學和人工智慧等技術的進步使研究人員能夠收集和分析大量數據，從而增加了對組織和解釋這些資訊的資訊學工具的需求。預計2024年市場規模將超過34.1億美元，2032年將達到約75.7億美元。

人們越來越重視針對特定疾病或患者群體的藥物開發，這推動了對更先進的藥物發現資訊系統的需求。對具有成本效益且高效的藥物發現資訊學的需求不斷成長，使得市場在 2026 年至 2032 年期間的複合年成長率達到 11.57%。

藥物發現資訊學市場定義/概述

藥物發現資訊學是應用計算工具和方法來改進藥物發現和開發過程。這個跨學科領域使用數據管理、生物資訊學、化學資訊學和先進的分析工具來查詢生物數據、化學特性和藥物交互作用。它可以幫助研究人員找到有希望的候選藥物，預測其功效和安全性，並最佳化其化學結構。應用包括虛擬化合物庫的篩檢、定量構效關係 (QSAR) 建模、生物標記識別和高通量篩檢資料的合成。藥物發現資訊學在現代藥物研究中至關重要，因為它可以加速藥物開發並增加成功的機會。

人工智慧 (AI)、機器學習和巨量資料分析的進步為藥物發現資訊學帶來了樂觀的前景。預計這些技術將大大提高預測建模能力，使研究人員能夠開發更有效、更有針對性的藥物。體學數據（基因組學、蛋白質組學、代謝體學）的整合可以更全面地了解疾病機制，並有助於確定新的治療目標。

隨著產業走向精準醫療，藥物發現資訊學有助於根據基因和分子特徵為特定患者群體量身定做候選藥物。雲端運算的日益普及將使世界各地的研究人員更輕鬆地協作，從而有可能加快藥物研發過程並改變新治療方法的開發方式。

製藥業研發支出的增加是否會推動藥物發現資訊學市場的發展？

製藥業研發支出的增加可能會推動藥物發現資訊學市場的發展。 2019年，製藥公司在研發方面投資了830億美元，較2008年的480億美元大幅成長，顯示了它們對創新和發現新藥的奉獻精神。大量資金投入研發中，對先進資訊學解決方案的需求日益成長，這些解決方案可以簡化和改進藥物發現過程，使研究人員能夠更有效地分析大量數據，識別有前景的候選藥物，並最終加快新藥上市的速度。

個人化醫療日益成長的需求正在推動藥物發現資訊學市場的發展。個人化醫療的爆炸性成長，佔 2018 年 FDA核准的新治療方法的 25%（高於 2005 年的 5%），顯示該產業致力於根據獨特的患者情況調整治療方法。這一趨勢凸顯了對改進資訊學工具的迫切需求，這些工具可以充分分析包括遺傳、環境和生活方式方面的廣泛數據。利用這些先進的資訊學解決方案，研發研究人員可以簡化藥物開發流程並改善治療結果，從而推動藥物發現資訊學市場的未來成長。

高成本會影響藥物發現資訊學市場的成長嗎？

高成本可能會影響藥物發現資訊學市場的成長。規模較小的製藥公司和新興企業可能難以注入先進資訊工具、資料管理系統和技術人員所需的大量資金。這些高成本可能會限制獲得最尖端科技的途徑，並延遲突破性資訊解決方案的採用。許多公司面臨的整體研發預算限制可能會導致藥物發現資訊學支出的下降，從而阻礙市場成長，因為公司優先考慮關鍵支出而不是高階數據分析能力。

缺乏標準化影響了藥物發現資訊學市場的成長。如果沒有全球認可的通訊協定和數據格式，跨多個平台整合和交換資訊就會變得困難，從而阻礙研究人員和機構之間的合作。當公司試圖整合不同的資料集和流程時，這種分散會導致效率低下，最終減緩藥物研發進程。缺乏標準會導致數據品質不一致，從而難以獲得準確的見解並阻礙對藥物發現資訊學解決方案的投資。

The expanding demand for drug discovery informatics, including the increasing complexity of drug discovery, the desire to accelerate drug development timeframes, and the growing emphasis on customized treatment. Advances in technologies such as genomics, proteomics, and artificial intelligence are allowing researchers to collect and analyze massive amounts of data, increasing the demand for informatics tools to organize and interpret this information. The market size surpass USD 3.41 Billion valued in 2024 to reach a valuation of around USD 7.57 Billion by 2032.

The growing emphasis on creating targeted medicines for particular diseases and patient populations is driving demand for more advanced drug discovery informatics systems. The rising demand for cost-effective and efficient drug discovery informatics is enabling the market grow at a CAGR of 11.57% from 2026 to 2032.

Drug Discovery Informatics Market: Definition/ Overview

Drug Discovery Informatics is the application of computational tools and approaches to improve the process of drug discovery and development. This multidisciplinary discipline uses data management, bioinformatics, cheminformatics, and advanced analytical tools to examine biological data, chemical characteristics, and medication interactions. It helps researchers find prospective medication candidates, forecast their efficacy and safety, and optimize their chemical structures. Applications include virtual compound libraries screening, quantitative structure-activity relationship (QSAR) modeling, biomarker identification, and high-throughput screening data integration. Drug Discovery Informatics is essential in current pharmaceutical research since it accelerates drug development and increases the likelihood of success.

Drug Discovery Informatics is looking optimistic, thanks to advances in artificial intelligence (AI), machine learning, and big data analytics. These technologies are projected to greatly improve predictive modeling skills, enabling researchers to develop more effective and tailored medicines. The integration of omics data (genomics, proteomics, and metabolomics) will allow for a more comprehensive knowledge of disease mechanisms, leading to the identification of new therapeutic targets.

As the industry moves toward precision medicine, medication Discovery Informatics will help tailor medication candidates to specific patient populations based on genetic and molecular characteristics. The growing use of cloud computing will allow researchers around globally to collaborate more easily, speeding up the drug discovery process and, ultimately, changing how new treatments are developed.

Will the Increasing R&D Expenditure in the Pharmaceutical Industry Drive the Drug Discovery Informatics Market?

The increasing R&D spending in the pharmaceutical industry will propel the Drug Discovery Informatics market. Pharmaceutical companies invested USD 83 Billion in R&D in 2019, a significant increase from USD 48 Billion in 2008, demonstrating their dedication to innovation and the discovery of novel medicines. The significant financial resources invested in R&D create an increased demand for advanced informatics solutions that streamline and improve the drug discovery process, allowing researchers to analyze massive amounts of data more efficiently, identify promising drug candidates, and ultimately accelerate the timeline for bringing new drugs to market.

The rising need for personalized medicine will propel the drug discovery informatics market. The enormous increase in personalized medications, which accounted for 25% of all new FDA-approved therapies in 2018 (up from 5% in 2005), demonstrates the industry's dedication to adapting treatments to unique patient profiles. This trend highlights the critical need for improved informatics tools capable of properly analyzing a wide range of data, including genetic, environmental, and lifestyle aspects. Researchers can use these sophisticated informatics solutions to streamline drug development processes and improve treatment outcomes, driving future growth in the drug discovery informatics market.

Will the High Costs Impact the Growth of the Drug Discovery Informatics Market?

High costs will have an impact on the growth of the drug discovery informatics market. Smaller pharmaceutical companies and startups may find it difficult to make the considerable financial commitment required for advanced informatics tools, data management systems, and qualified personnel. These high costs may limit access to cutting-edge technologies, thereby stalling the adoption of breakthrough informatics solutions. The overall R&D budget constraints experienced by many organizations may result in reduced spending on drug discovery informatics, impeding market growth as companies prioritize vital expenditures over advanced data analytics capabilities.

The lack of standardization will have an impact on the growth of the drug discovery informatics market. Without globally acknowledged protocols and data formats, integrating and exchanging information across several platforms becomes difficult, thereby hindering collaboration among researchers and institutions. This fragmentation may result in inefficiencies as businesses attempt to integrate disparate data sets and processes, eventually slowing the drug discovery process. The lack of standards might result in variable data quality, making it difficult to obtain accurate insights and discouraging investment in drug discovery informatics solutions.

Category-Wise Acumens

What Factors Expand the Use of the Drug Discovery Informatics Market?

Sequencing & trial data management is currently the dominant segment in the drug discovery informatics market. The increasing availability of high-throughput sequencing technology will propel the sequencing & trial data management segment. These sophisticated technologies allow researchers to generate massive amounts of genetic data rapidly and inexpensively, greatly improving the ability to perform large-scale investigations and clinical trials. As the volume of sequencing data increases, there is a greater demand for comprehensive data management solutions that can efficiently process, analyze, and interpret this information.

The growth in genome data will propel the sequencing & trial data management segment. As genome sequencing technology evolves, the amount of data generated grows exponentially, necessitating the development of sophisticated data management solutions capable of efficiently storing, processing, and analyzing such huge amounts of information. This demand is driven by the need for researchers and clinicians to incorporate genetic data into their workflows, enabling customized medicine and more targeted therapeutic methods.

What Factors Boost the Use of the Drug Discovery Informatics Market?

Pharmaceutical and biotechnology companies are experiencing rapid growth segment in the drug discovery informatics market. Heavy investment in research and development (R&D) propels the Pharmaceutical & Biotechnology Companies Segment of the Drug Discovery Informatics Market, encouraging innovation and improving the drug discovery process. Pharmaceutical and biotech companies, which spent $83 billion on R&D in 2019, are increasingly looking for advanced informatics solutions to handle and analyze the massive amounts of data created during the discovery phase. This financing enables enterprises to capitalize on data-driven insights, increase candidate screening efficiency, and speed the development of new therapies.

The pharmaceutical & biotechnology companies segment of the drug discovery informatics market is likely to be driven by enhanced efficiency and cost reduction. As more companies use advanced informatics solutions, they can streamline their drug discovery processes, significantly reducing the time and resources required to bring new therapies to market. These efficiencies are accomplished by improving data management, predictive modeling, and automating procedures to decrease manual errors and redundancies. By cutting operational costs and increasing efficiency, pharmaceutical and biotechnology companies may devote more resources to innovation and competitive advantage, driving up demand for drug discovery informatics tools.

Country/Region-wise Acumens

Will the Advanced Research Institutions in the North American Region Propel the Drug Discovery Informatics Market?

North America leads the drug discovery informatics market. Advanced research institutions in North America will expand the drug discovery informatics market. These institutions are essential to encouraging innovation and growth, as indicated by the National Science Foundation's estimate that U.S. colleges and universities will invest USD 89.9 Billion in research and development in fiscal year 2021, with life sciences accounting for 56% of this expenditure. The National Institutes of Health (NIH) is further supporting this growth with a USD 39.2 Billion investment in medical research for fiscal year 2023, to improve drug discovery technologies and leverage artificial intelligence to potentially reduce early-stage drug development costs by 30-50% while shortening timelines.

The strong pharmaceutical and biotechnology industry in North America will power the drug discovery informatics market. In 2021, the U.S. biopharmaceutical industry would invest around USD 102.3 Billion in research and development, increasing need for advanced informatics tools to improve R&D efficiency and productivity. The FDA announced that 37 innovative medications were authorized in 2022, with many relying on sophisticated informatics and computational methodologies. By 2025, it is expected that more than half of new drug applications will use model-based research. The presence of over 6,441 biotech businesses actively embracing AI and machine learning, together with the NIH's funding of USD 1.5 Billion for biomedical informatics in 2023, demonstrates the robust investment and innovation that will drive the growth of the drug discovery informatics market.

Will the Rising Awareness of Drug Discovery Informatics Lead the Asian Pacific Region for the Drug Discovery Informatics Market?

The Asia-Pacific region is experiencing the fastest growth in the drug discovery informatics market. The growing awareness of drug discovery informatics is likely to propel the drug discovery informatics market in the Asia-Pacific region. Increased investments in drug discovery technology, particularly in nations such as India, which wants to have a USD 150 Billion biotech industry by 2025, and China, where AI-powered drug discovery companies have risen tenfold since 2018, highlight this trend. role in advancing the development of novel treatments to satisfy a variety of health needs.

The cost-effective labor in the Asia-Pacific region is a major driver of the drug discovery informatics market. The average salary for skilled biotechnology professionals in India is just $15,000, compared to $85,000 in the United States, making it financially appealing for pharmaceutical corporations to set up R&D units there. Since 2020, the number of bioinformatics specialists in the region has increased by 35%, with more growth expected. Outsourcing drug development efforts to Asia-Pacific can lower R&D costs by 25-45%, prompting more than 60% of global pharmaceutical corporations to build operations in the region by 2025. The combination of low-cost skilled labor and an expanding talent pool puts Asia-Pacific as a major participant in drug discovery informatics.

Competitive Landscape

The drug discovery informatics market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the drug discovery informatics market include:

Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery, Inc., Selvita, Charles River Laboratories, Inc., Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, Dassault Systemes.

Latest Developments

In April 2024, Sapio Sciences, the science-aware lab informatics platform, now supports multimodal registration. It combines small-molecule, large-molecule, and multimodal discovery methods, including entity registration, into a single platform.
In February 2023, Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (Al)-driven drug discovery business, revealed that it has received the FDA Orphan Drug Designation for its AI-discovered and designed medication for idiopathic pulmonary fibrosis.

1 INTRODUCTION OF GLOBAL DRUG DISCOVERY INFORMATICS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DRUG DISCOVERY INFORMATICS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY APPLICATION

5.1 Overview
5.2 Drug Discovery
5.3 Drug Development

6 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY FUNCTION

6.1 Overview
6.2 Sequence Analysis Platforms
6.3 Molecular Modelling
6.4 Docking
6.5 Sequencing & Trial Data Management

7 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY END-USER

7.1 Overview
7.2 Pharmaceutical & Biotechnology Companies
7.3 Contract Research Organizations

8 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Argentina
8.6 Rest of the World

9 GLOBAL DRUG DISCOVERY INFORMATICS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES

10.1 Thermo Fisher Scientific, Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 PerkinElmer, Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Certara, L.P.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Infosys Limited
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Novo Informatics Pvt. Ltd.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Collaborative Drug Discovery Inc.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Selvita
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Charles River Laboratories, Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Jubilant Life Sciences Ltd.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 IO Informatics, Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments